Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations - PubMed (original) (raw)
. 2001 Jun 14;20(27):3553-62.
doi: 10.1038/sj.onc.1204465.
Affiliations
- PMID: 11429702
- DOI: 10.1038/sj.onc.1204465
Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations
D Ronchetti et al. Oncogene. 2001.
Abstract
The t(4;14)(p16.3;q32) chromosomal translocation occurs in approximately 20% of multiple myelomas (MM) and leads to the apparent deregulation of two genes located on 4p16.3: the fibroblast growth factor receptor 3 (FGFR3) and the putative transcription factor WHSC1/MMSET. Interestingly, FGFR3 mutations known to be associated with autosomal dominant human skeletal disorders have also been found in some MM cell lines with t(4;14) but their pathogenetic role in MM is still controversial. Since cell lines may represent useful models for investigating the effects of deregulated FGFR3 mutants in MM, we analysed the expression, activation, signaling pathways and oncogenic potential of three mutants identified so far: the Y373C and K650E in the KMS-11 and OPM-2 cell lines respectively, and the novel G384D mutation here identified in the KMS-18 cell line. All of the cell lines present a heterozygous FGFR3 gene mutation and transcribe the mutated allele; unlike KMS-11 and OPM-2 (which express the IIIc isoform), the KMS-18 cell line expresses prevalently the isoform IIIb. We demonstrated that, under serum-starved conditions, KMS-11 and OPM-2 cells express appreciable levels of phosphorylated FGFR3 mutants indicating a constitutive activation of the Y373C and K650E receptors; the addition of the aFGF ligand further increased the level of receptor phosphorylation. Conversely, the FGFR3 mutant in KMS-18 does not seem to be constitutively activated since it was phosphorylated only in the presence of the ligand. In all three MM cell lines, ligand-stimulated FGFR3 mutants activated the MAP kinase signaling pathway but did not apparently involve either the STAT1 or STAT3 cascades. However, when transfected in 293T cells, G384D, like Y373C and K650E, was capable of activating MAPK, STAT1 and STAT3 under serum-starved condition. Finally, a focus formation assay of NIH3T3 cells transfected with FGFR3-expressing plasmid vectors showed that Y373C and K650E (albeit at different levels) but not G384D or the wild-type receptor, can induce transformed foci. Overall, our results support the idea that FGFR3 mutations are graded in terms of their activation capability, thus suggesting that they may play a critical role in the tumor progression of MM patients with t(4;14).
Similar articles
- Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization.
Adar R, Monsonego-Ornan E, David P, Yayon A. Adar R, et al. J Bone Miner Res. 2002 May;17(5):860-8. doi: 10.1359/jbmr.2002.17.5.860. J Bone Miner Res. 2002. PMID: 12009017 - Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, Tynan JA, Donoghue DJ. Hart KC, et al. Oncogene. 2000 Jul 6;19(29):3309-20. doi: 10.1038/sj.onc.1203650. Oncogene. 2000. PMID: 10918587 - Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation.
Otsuki T, Yamada O, Yata K, Sakaguchi H, Kurebayashi J, Nakazawa N, Taniwaki M, Yawata Y, Ueki A. Otsuki T, et al. Int J Oncol. 1999 Dec;15(6):1205-12. doi: 10.3892/ijo.15.6.1205. Int J Oncol. 1999. PMID: 10568829 - FGF receptor mutations: dimerization syndromes, cell growth suppression, and animal models.
Kannan K, Givol D. Kannan K, et al. IUBMB Life. 2000 Mar;49(3):197-205. doi: 10.1080/713803609. IUBMB Life. 2000. PMID: 10868910 Review. - Cell responses to FGFR3 signalling: growth, differentiation and apoptosis.
L'Hôte CG, Knowles MA. L'Hôte CG, et al. Exp Cell Res. 2005 Apr 1;304(2):417-31. doi: 10.1016/j.yexcr.2004.11.012. Epub 2004 Dec 16. Exp Cell Res. 2005. PMID: 15748888 Review.
Cited by
- APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma.
Walker BA, Wardell CP, Murison A, Boyle EM, Begum DB, Dahir NM, Proszek PZ, Melchor L, Pawlyn C, Kaiser MF, Johnson DC, Qiang YW, Jones JR, Cairns DA, Gregory WM, Owen RG, Cook G, Drayson MT, Jackson GH, Davies FE, Morgan GJ. Walker BA, et al. Nat Commun. 2015 Apr 23;6:6997. doi: 10.1038/ncomms7997. Nat Commun. 2015. PMID: 25904160 Free PMC article. - N822K- or V560G-mutated KIT activation preferentially occurs in lipid rafts of the Golgi apparatus in leukemia cells.
Obata Y, Hara Y, Shiina I, Murata T, Tasaki Y, Suzuki K, Ito K, Tsugawa S, Yamawaki K, Takahashi T, Okamoto K, Nishida T, Abe R. Obata Y, et al. Cell Commun Signal. 2019 Sep 4;17(1):114. doi: 10.1186/s12964-019-0426-3. Cell Commun Signal. 2019. PMID: 31484543 Free PMC article. - Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.
Tomlinson DC, Hurst CD, Knowles MA. Tomlinson DC, et al. Oncogene. 2007 Aug 30;26(40):5889-99. doi: 10.1038/sj.onc.1210399. Epub 2007 Mar 26. Oncogene. 2007. PMID: 17384684 Free PMC article. - The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma.
Giacomini A, Taranto S, Gazzaroli G, Faletti J, Capoferri D, Marcheselli R, Sciumè M, Presta M, Sacco A, Roccaro AM. Giacomini A, et al. J Exp Clin Cancer Res. 2024 Nov 1;43(1):294. doi: 10.1186/s13046-024-03217-2. J Exp Clin Cancer Res. 2024. PMID: 39482742 Free PMC article. Review. - Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype.
Murakami S, Balmes G, McKinney S, Zhang Z, Givol D, de Crombrugghe B. Murakami S, et al. Genes Dev. 2004 Feb 1;18(3):290-305. doi: 10.1101/gad.1179104. Genes Dev. 2004. PMID: 14871928 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous